Phathom Pharmaceuticals Inc. (PHAT) Prices 2.25M Share Common Offering at $42/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Phathom Pharmaceuticals Inc. (PHAT) Announces Proposed 2.5M Common Share Offering
December 15, 2020 4:02 PM ESTPhathom Pharmaceuticals, Inc. (NASDAQ: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, 2,250,000 shares of its common stock in an underwritten public... More
Phathom Pharmaceuticals (PHAT) PT Raised to $55 at Needham & Company
December 15, 2020 8:42 AM ESTNeedham & Company analyst Alan Carr raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $55.00 (from $45.00) while maintaining a Buy rating.
The analyst commented, "Phathom hosted a virtual R&D event and announced plans to initiate Phase 2 testing of vonoprazan in... More
